Endocrine Abstracts

Hypoparathyroidism is a rare disease characterized by a deficiency in parathyroid hormone (PTH) that results in hypocalcemia and hyperphosphatemia. Current treatment approaches, including high dose oral calcium and active vitamin D, as well as recombinant human PTH (1–84), do not provide adequate or consistent control of either serum calcium or clinical symptoms over a full 24-hour period. AZP-3601 is a novel 36 amino-acid PTH analog that has been designed to potently bi...

Maintaining normal serum and urinary calcium in patients with chronic hypoparathyroidism (cHP) remains a therapeutic challenge. Parathyroid hormone (PTH) replacement therapy is not ideal due to its short half-life and transient activation of the PTH 1 receptor (PTH1R). Eneboparatide is a hybrid analog of PTH and PTH-related peptide specifically designed to induce prolonged activation of the PTH1R. Despite a short half-life, eneboparatide is able to normalize serum and urinary ...

Insulin-like growth factor binding protein-2 (IGFBP2) has been demonstrated to be a key mediator of the peripheral actions of leptin, and its deficiency is associated with impaired metabolic function. The metabolic activity of IGFBP2 can be localized to a unique heparin-binding domain (HBD-1) within its structure. AZP-3404 is a 9-amino acid analog of the IGFBP2 HBD-1 that has been demonstrated to increase glucose uptake by differentiated mouse myotubes in vitro, and to increas...

Introduction: In chronic hypoparathyroidism (cHP), hypercalciuria is frequent, the mechanism of which remains unclear. The repetition of episodes of urinary tract obstruction by lithiasis can play a key role in the progressive deterioration of renal function. Taking advantage of the prospective cohort Epi-Hypo, we examined the relationship between nephrolithiasis and hypercalciuria.Methods: The Epi-Hypo cohort started in 2016 in France and is still activ...

Introduction: In Chronic hypoparathyroidism (cHP), secretion of parathyroid hormone (PTH) is insufficient to maintain blood calcium concentration (PCa) steady. More than 70% of cases result from neck surgery and therefore in insufficient secretion of PTH as in mutations of genes involved in PTH synthesis, while mutations of the calcium-sensing receptor (CaSR) and its signaling pathway may result in a remaining secretion of PTH. cHP can exert nephrocalcinosis and/or nephrolithi...

Background: Acromegaly is a rare disease typically caused by a benign growth hormone (GH)-secreting pituitary adenoma that stimulates over-production of insulin-like growth factor-1 (IGF1) from the liver. Treatment with somatostatin analog (SSA) monotherapy does not provide optimal control of circulating IGF-1 levels in the majority of patients. AZP-3813, a 16-amino acid, bicyclic GH receptor antagonist (GHRA) binds to the GH receptor and prevents endogenous GH from stimulatin...

Background: Conventional therapy for chronic hypoparathyroidism (cHP) is often unable to maintain stable normal serum calcium (Ca) levels for a full 24 h, to control symptoms, to prevent the detrimental long-term effects on the kidney and to preserve normal bone architecture. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide specifically designed to activate the R0 conformation of the PTH receptor 1, that results in a prolonged calcemic response and a sustai...

Background: Conventional therapy with oral calcium (Ca) and active vitamin D (vitD) supplementation for chronic hypoparathyroidism (cHP) can induce or aggravate hypercalciuria and may lead to detrimental long-term renal complications. Eneboparatide (AZP-3601) is a novel 36-amino-acid peptide with a short half-life designed to activate the R0 conformation of the PTH 1 receptor which produces a prolonged calcemic response. This phase 2a study examined the effects of e...

Introduction: The HypoparaNet database includes 509 patients (110 men and 399 women) with chronic hypoparathyroidism (cHP), recruited and followed in 20 clinical centers in Italy from 2014 onwards. cHP etiology included 363 post-surgical cases (71.3%), 78 idiopathic cases (15.3%), and 64 patients with a genetic background (12.6%). Bone health is an important clinical aspect to be considered in patients with cHP, whose skeleton is exposed both to the cHP-induced alteration of b...